YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar, that is now interchangeable [1] Interchangeable designation of YUFLYMA® is supported by positive data from the Phase III interchangeability study in patients with...
Hence then, the article about u s fda grants interchangeable designation to yuflyma adalimumab aaty celltrion s biosimilar to humira adalimumab was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( U.S. FDA grants interchangeable designation to YUFLYMA® (adalimumab-aaty), Celltrion's biosimilar to Humira® (adalimumab) )
Also on site :
- Lauren Chapin, the Youngest Kid on ‘Father Knows Best,’ Dies at 80
- Aldi's is Selling a Versatile $6 Meal Prep Essential Home Cooks Will Love
- S.S. Rajamouli Unveils Motion Capture Facility at Nagarjuna’s Annapurna Studios; Key ‘Varanasi’ Sequences Shot at Lab (EXCLUSIVE)